""
vom 26.07.2017

First joint symposium of Cancer Core Europe and nationwide Cancer Institutions

 

 

 

European lymphoma experts met in Heidelberg for the „Cancer Core Europe Conference on Lymphoma 2016“at the end of January 2016.  

On January 22nd 2016, the first joint symposium Cancer Core Europe (CCE) and the German Consortium for Translational Cancer Research (DKTK) took place at the German Cancer Research Center (DKFZ) in Heidelberg.  More than 140 scientists and participants from all over Europe exchanged new scientific and therapeutic findings of malignant lymphomas.

The symposium was organized by the National Center for Tumor Diseases (NCT) Heidelberg. The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg and the German Cancer Aid.

Six European cancer institutes merged in 2014 to form the cancer consortium Cancer Core Europe. To the consortium belong the DKFZ and National Center for Tumor Diseases (NCT) Heidelberg, the Gustave Roussy Cancer Campus in Villejuif, France, the British Cambridge Cancer Center, the Karolinska Institute in Stockholm, the Netherland Cancer Institute in Amsterdam and the Vall d’Hebron Institute of Oncology in Barcelona.

„Our goal is to intensify our cooperation in cancer research and cancer medication across national borders“, explains Professor Fabien Calvo, Scientific Director of Cancer Core Europe, in his opening lecture.  Together, a virtual e-hospital is shall be established in order to standardize medical and scientific processes and build a “translational platform” for joint clinical studies. The institutions of the Cancer Core Europe treat annually about 60.000 patients with newly diagnosed cancer and implement 300.000 tumor treatments. The consortium partners accomplish about one million outpatient-visits every year and conduct 1500 clinical trials.

„In order to be able to work this interconnected, intensive exchange is inevitable. With the Cancer Core Europe conference, we want to establish another power-wheel to advance projects in blood cancer and lymphoma together” says Professor Thorsten Zenz from the NCT and organizer of the Lymphoma-Conference 2016. A continuation with other focus areas is planned in the following years.

10 to 15 people out of 100.000 are diagnosed with malignant lymphomas each year, a group of malignant cancer diseases of the lymphatic system.  The diagnosis of lymphomas is demanding, due to many existing subgroups. Physicians were able to achieve distinct advancements in healing prognosis in some forms of lymphoma in the last 30 years. However, the prognoses of patients with T-cell lymphomas or aggressive lymphomas, who do not respond to therapy, are still unsatisfactory. Especially new results for the therapy in b-cell lymphomas with targeted inhibitors, terminating essential ways of signaling, gained attention during the event of one day. Martin Dreyling from Munich, Kieron Dunleavy from Bethesda and Susan O’Brien from Irvine presented impressive results for chronic lymphatic leukemia (CLL), mantel cell lymphoma (MCL) and lymphomas of the central nervous system among others.